
© 2024 Moneycab
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | RBC upgrades Sandoz to "outperform," sees 24% upside on biosimilar growth | ||
Fr | Neuer Schub für Sandoz | ||
Mi | Sandoz Q1 2025 slides: Biosimilars drive 3% sales growth as company confirms full-year guidance | ||
Mi | Sandoz Group: Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed | Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE
Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1]... ► Artikel lesen | |
29.04. | Sandoz geht Kommerz-Kooperation mit Henlius zu Krebstherapie Ipilimumab ein |